We tested the hypothesis that prophylactic cardiac-resynchronization therapy in the form of biventricular stimulation with a pacemaker with or without a defibrillator would reduce the risk of death ...
Receipt of a cardiac-resynchronization therapy-defibrillator (CRT-D) offers long term benefit for patients with heart failure, reduced ejection fraction, and a widened QRS complex, according to a ...
Intraventricular conduction delays are found in 15–30% of patients suffering from advanced chronic heart failure and lead to a reduction in systolic function and increased systolic volume. In ...
Shanghai, China - The first patient implants of the Boston Scientific Corporation COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) were successfully performed in China’s Zhejiang ...
Please provide your email address to receive an email when new articles are posted on . Long-term CRT-D use was tied to improved survival and time to adverse events vs. ICD therapy in patients with ...
Patients who need cardiac resynchronization therapy may be eligible for Cedars-Sinai clinical trials
LOS ANGELES (March 8, 2002) – Patients who suffer from advanced congestive heart failure and heart rhythm abnormalities may qualify to participate in one of two research trials now underway at ...
Medtronic CRT-D Devices Demonstrate Survival Benefits for Mildly Symptomatic Heart Failure Patients in Two Pivotal Clinical Trials MINNEAPOLIS – Medtronic, Inc. today announced that the U.S. Food and ...
BIOTRONIK today announced the launch of the new Acticor Sky and Rivacor Sky device family featuring the world's first CE-approved left bundle branch area pacing (LBBAP) high-voltage device. These next ...
Defibrillators, with or without cardiac resynchronization therapy, can reduce the rate of sudden death. However, shocks are unpleasant, often unnecessary, and can damage myocardium or defibrillator ...
The European Society of Cardiology (ESC) has released updated guidelines for cardiac pacing and cardiac resynchronization therapy (CRT), which emphasize patient-centered care and shared ...
DUBLIN, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it has received CE (Conformité Européenne) Mark for its Cobalt™ and Crome™ portfolio of implantable ...
The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results